16 Mai 2019

Arkema selects Singapore for the production of its Rilsan® high-performance bio-sourced polyamides

With 50% increase, Group supports strong demand from its customers in Asia for high-performance bio-sourced solutions

ATO_3375_2030.jpg_1134140949Arkema has chosen the location of Jurong Island in Singapore to build its new world-scale plant dedicated to the manufacture of the amino 11 monomer and its flagship Rilsan® polyamide 11 resins. With this 50% increase in its global capacities announced in July 2017, the Group supports strong demand from its customers in Asia for high-performance bio-sourced solutions addressing the major opportunity of material lightweighting in particular.

Arkema has chosen the Jurong Island site in Singapore to set up its new bio-sourced polyamide production site. This location offers many advantages in terms of infrastructure, logistics, industrial integration and operational excellence, as well as optimization of the activity’s carbon footprint.

“This major investment bolsters our global presence in bio-sourced materials while bringing us significantly closer to our customers in Asia. Singapore’s industrial and innovation-friendly environment is, we believe, a key asset for our project.” (Erwoan Pezron, Global Group President for Arkema’s Technical Polymers business line)

Rilsan® polyamide 11 is derived from castor oil and so is the only 100% bio-sourced polyamide approved for many of the most demanding applications, in particular in the electronics, 3D printing, oil and gas extraction, and automotive markets, as a substitute to metal.

This project is part of the Group’s exceptional investments totaling some 500 million euros earmarked for the 2018-2021 period essentially. Construction is scheduled to be completed by late 2021.

Source: Arkema, press release, 2019-05-03.

Share on Twitter+1Share on FacebookShare on XingShare on LinkedInShare via email